Susquehanna International Group’s Inhibrx INBX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.55M Sell
52,800
-72,300
-58% -$5.36M ﹤0.01% 4912
2025
Q4
$9.88M Buy
125,100
+104,500
+507% +$7.12M ﹤0.01% 3056
2025
Q3
$694K Buy
+20,600
New +$507K ﹤0.01% 8216
2025
Q2
Sell
-35,500
Closed -$497K 13165
2025
Q1
$497K Buy
35,500
+16,300
+85% +$221K ﹤0.01% 8920
2024
Q4
$296K Sell
19,200
-16,600
-46% -$253K ﹤0.01% 9862
2024
Q3
$561K Buy
35,800
+18,000
+101% +$253K ﹤0.01% 8191
2024
Q2
$252K Buy
+17,800
New +$278K ﹤0.01% 9838

Other funds holding INBX

Susquehanna International Group's INBX Position: Q1 2026 in Review

Susquehanna International Group reduced its Inhibrx (INBX) stake by 67% in Q1 2026, selling an estimated $14.8M and leaving 97,873 shares worth $6.58M. The position accounts for ﹤0.01% of the portfolio, ranked #3778.

Susquehanna International Group first reported a position in INBX in Q2 2024 and has held it in 7 quarters since. The position peaked at $23.5M in Q4 2025. 135 funds tracked by Wall St. Rank hold INBX as of Q1 2026.

  • Susquehanna International Group held 97,873 shares of Inhibrx worth $6.58M as of Q1 2026.
  • Susquehanna International Group sold 199,243 Inhibrx shares in Q1 2026, an estimated $14.8M.
  • Inhibrx made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #3778 holding.
  • Susquehanna International Group first reported a position in Inhibrx in Q2 2024 and has held it in 7 quarters since.
  • Susquehanna International Group's Inhibrx position peaked at $23.5M in Q4 2025.
  • 135 funds tracked by Wall St. Rank held Inhibrx as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.